Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Volunteers Only Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers

NCT02761980
View directory record Official record
Conditions
Fever
Interventions
Ibuprofen 250 mg / Acetaminophen 500 mg, Ibuprofen 250 mg, Acetaminophen 500 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

NCT06435923
View directory record Official record
Conditions
Healthy Participants
Interventions
[14C]-darigabat
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

NCT05642546
View directory record Official record
Conditions
Healthy
Interventions
NM8074, Placebo
Drug
Lead sponsor
NovelMed Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines

NCT05074459
View directory record Official record
Conditions
Healthy Participants
Interventions
Eptinezumab Mammalian Cell Line, Eptinezumab Yeast Cell Line
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

NCT05056246
View directory record Official record
Conditions
Healthy Participants
Interventions
AMG 133
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

NCT06072157
View directory record Official record
Conditions
Healthy Participants, Chronic Spontaneous Urticaria
Interventions
AK006-IV, Placebo-IV, AK006-SC, Placebo-SC
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg

NCT00648557
View directory record Official record
Conditions
Healthy
Interventions
Levothyroxine Sodium Tablets 200 mg, Synthroid Tablets 200 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jun 10, 2026, 2:27 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.

NCT01011257
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Asprin, Clopidogrel
Drug
Lead sponsor
Neil Kleiman, MD
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

NCT01837719
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions
Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

NCT02342067
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Pioglitazone
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

NCT01833754
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study

NCT04749745
View directory record Official record
Conditions
Cortical Excitability, Psychiatric Disorder
Interventions
L-theanine, Placebo
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

NCT02387866
View directory record Official record
Conditions
Healthy
Interventions
AG-221
Drug
Lead sponsor
Celgene
Industry
Eligibility
20 Years to 50 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

NCT02343133
View directory record Official record
Conditions
Hematopoietic Syndrome Due to Acute Radiation Syndrome
Interventions
HemaMax, Placebo
Biological · Drug
Lead sponsor
Neumedicines Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

NCT03127189
View directory record Official record
Conditions
Healthy
Interventions
Rilpivirine, Rilpivirine Long-acting Parenteral Formulation
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Scopolamine in Healthy Volunteers

NCT03874130
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

NCT02723630
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenvatinib 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

NCT06385119
View directory record Official record
Conditions
Healthy Participants
Interventions
Plixorafenib, Cobicistat
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet

NCT00917644
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin
Drug · Genetic
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04128293
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 Tablet, GSK3640254 Capsule
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector

NCT05264493
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NaxRedy ™, Naloxone Hydrochloride Injection, USP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bioavailability Study for New Atorvastatin Formulation

NCT00844376
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin suspension, Lipitor
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

NCT04504448
View directory record Official record
Conditions
Healthy
Interventions
HNC664 capsules Single dose, HNC664 placebos Single dose, HNC664 capsules FED
Drug
Lead sponsor
Guangzhou Henovcom Bioscience Co. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

NCT00551317
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib (SB480848)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jun 10, 2026, 2:27 PM EDT